Activest Wealth Management Has $100,000 Position in Pfizer Inc. (NYSE:PFE)

Activest Wealth Management trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 9.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,752 shares of the biopharmaceutical company’s stock after selling 403 shares during the quarter. Activest Wealth Management’s holdings in Pfizer were worth $100,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. V2 Financial group LLC raised its stake in shares of Pfizer by 20.6% in the fourth quarter. V2 Financial group LLC now owns 29,671 shares of the biopharmaceutical company’s stock worth $787,000 after acquiring an additional 5,071 shares during the last quarter. Wilsey Asset Management Inc. lifted its stake in shares of Pfizer by 7.0% during the fourth quarter. Wilsey Asset Management Inc. now owns 883,357 shares of the biopharmaceutical company’s stock valued at $23,435,000 after acquiring an additional 57,572 shares during the period. Newbridge Financial Services Group Inc. bought a new position in Pfizer in the fourth quarter valued at about $395,000. Kestra Private Wealth Services LLC increased its position in Pfizer by 2.8% in the fourth quarter. Kestra Private Wealth Services LLC now owns 296,263 shares of the biopharmaceutical company’s stock worth $7,860,000 after purchasing an additional 8,069 shares during the period. Finally, Howland Capital Management LLC raised its holdings in Pfizer by 5.3% during the 4th quarter. Howland Capital Management LLC now owns 62,501 shares of the biopharmaceutical company’s stock worth $1,658,000 after purchasing an additional 3,164 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on PFE shares. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Guggenheim dropped their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Down 0.3 %

Pfizer stock opened at $25.76 on Monday. The company has a 50 day moving average of $26.28 and a 200-day moving average of $27.73. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a market capitalization of $145.96 billion, a PE ratio of 18.27, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the business earned $0.10 EPS. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.68%. Pfizer’s payout ratio is presently 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.